Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

L. Watson; B. J. Wilson; Norman Robert Waugh

doi:10.1016/S0264-410X(02)00112-3

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

L. Watson, B. J. Wilson, Norman Robert Waugh

Applied Health Sciences

Research output: Contribution to journal › Article › peer-review

121 Citations (Scopus)

Abstract

Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

Original language	English
Pages (from-to)	2166-2173
Number of pages	7
Journal	Vaccine
Volume	20
Issue number	17-18
DOIs	https://doi.org/10.1016/S0264-410X(02)00112-3
Publication status	Published - 2002

Keywords

vaccination
pneumococcal
review
RANDOMIZED CONTROLLED TRIALS
OBSTRUCTIVE PULMONARY-DISEASE
PROTECTIVE EFFICACY
ELDERLY PEOPLE
PNEUMONIA
QUALITY
RECOMMENDATIONS
METAANALYSIS
PREVENTION
SEROTYPE

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(02)00112-3

Cite this

@article{08611d89ac264059875d02f3e1fbc7b5,

title = "Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults",

abstract = "Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.",

keywords = "vaccination, pneumococcal, review, RANDOMIZED CONTROLLED TRIALS, OBSTRUCTIVE PULMONARY-DISEASE, PROTECTIVE EFFICACY, ELDERLY PEOPLE, PNEUMONIA, QUALITY, RECOMMENDATIONS, METAANALYSIS, PREVENTION, SEROTYPE",

author = "L. Watson and Wilson, {B. J.} and Waugh, {Norman Robert}",

year = "2002",

doi = "10.1016/S0264-410X(02)00112-3",

language = "English",

volume = "20",

pages = "2166--2173",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "17-18",

}

TY - JOUR

T1 - Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

AU - Watson, L.

AU - Wilson, B. J.

AU - Waugh, Norman Robert

PY - 2002

Y1 - 2002

N2 - Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

AB - Pneumococcal polysaccharide vaccine is recommended in western countries for individuals at high risk of pneumococcal illness. We undertook a systematic review of randomised controlled trials of pneumococcal vaccine in adults, to determine the effects on clinical outcomes. Results: In industrialised populations, no benefit was detected for outcomes other than pneumococcal bacteraemia, and thin, did not reach statistical significance. In non-industrial populations, clear benefit was demonstrated for mortality and all-cause pneumonia. Conclusion: Benefit from pneumococcal vaccination depends on the baseline risk of infection and characteristics of a given population. Evidence from randomised trials for widespread adult vaccination in industrial countries is lacking. (C) 2002 Elsevier Science Ltd. All rights reserved.

KW - vaccination

KW - pneumococcal

KW - review

KW - RANDOMIZED CONTROLLED TRIALS

KW - OBSTRUCTIVE PULMONARY-DISEASE

KW - PROTECTIVE EFFICACY

KW - ELDERLY PEOPLE

KW - PNEUMONIA

KW - QUALITY

KW - RECOMMENDATIONS

KW - METAANALYSIS

KW - PREVENTION

KW - SEROTYPE

U2 - 10.1016/S0264-410X(02)00112-3

DO - 10.1016/S0264-410X(02)00112-3

M3 - Article

VL - 20

SP - 2166

EP - 2173

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -

Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this